The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Comparison of Dopamine and Norepinephrine in the Treatment of Shock
Open accessAbstract
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0.19 microg per kilogram per minute for norepinephrine, open-label norepinephrine, epinephrine, or vasopressin could be added. The primary outcome was the rate of death at 28 days after randomization; secondary end points included the number of days without need for organ support and the occurrence of adverse events. RESULTS: The trial included 1679 patients, of whom 858 were assigned to dopamine and 821 to norepinephrine. The baseline characteristics of the groups were similar. There was no significant between-group difference in the rate of death at 28 days (52.5% in the dopamine group and 48.5% in the norepinephrine group; odds ratio with dopamine, 1.17; 95% confidence interval, 0.97 to 1.42; P=0.10). However, there were more arrhythmic events among the patients treated with dopamine than among those treated with norepinephrine (207 events [24.1%] vs. 102 events [12.4%], P<0.001). A subgroup analysis showed that dopamine, as compared with norepinephrine, was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock (P=0.03 for cardiogenic shock, P=0.19 for septic shock, and P=0.84 for hypovolemic shock, in Kaplan-Meier analyses). CONCLUSIONS: Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dopamine (DA) is a neurotransmitter in the catechol family, which is often used as first-line vasoactive drug in patients with septic shock (43).”
From Dopamine Is a Siderophore-Like Iron Chelator That Promotes Salmonella enterica Serovar Typhimurium Virulence in Mice (2019) · cites this paper as [43]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Self-citationWriting Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationCDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Müllner, M., Urbanek, B., Havel, C., Losert, H., Gamper, G., & Herkner, H. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003709.pub2 · Cited by 654
Research works printed but not linked: 1
- Mullner M, 2004, Cochrane Database Syst Rev, 3, CD003709
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Self-citationThe Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
“[152] 182”
Self-citationAuthors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
“A subgroup analysis suggested that norepinephrine would have fewer side effects and lower mortality.(558) Epinephrine (adrenaline) should be restricted to patients with persistent hypotension despite adequate cardiac filling pressures and the use of other vasoactive agents, as well as for resuscitation protocols.”
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
Severe Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
“However, there were more arrhythmic events among the patients treated with dopamine [30].”
Background2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Peberdy, M. A., Callaway, C. W., Neumar, R. W., Geocadin, R. G., Zimmerman, J. L., Donnino, M., Gabrielli, A., Silvers, S. M., Zaritsky, A. L., Merchant, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.971002 · Cited by 2,522
Cecconi, M., Evans, L., Levy, M., & Rhodes, A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30696-2 · Cited by 2,254
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Kleinman, M. E., Chameides, L., Schexnayder, S. M., Samson, R. A., Hazinski, M. F., Atkins, D. L., Berg, M. D., de Caen, A. R., Fink, E. L., Freid, E. B., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.971101 · Cited by 1,949
van Diepen, S., Katz, J. N., Albert, N. M., Henry, T. D., Jacobs, A. K., Kapur, N. K., Kilic, A., Menon, V., Ohman, E. M., Sweitzer, N. K., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000525 · Cited by 1,869
Cecconi, M., De Backer, D., Antonelli, M., Beale, R., Bakker, J., Hofer, C., Jaeschke, R., Mebazaa, A., Pinsky, M. R., Teboul, J. L., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3525-z · Cited by 1,767
“In the 1,679 ICU patients in the European Sepsis Occurrence in Acutely Ill Patients II (SOAP II) trial, septic shock was the most frequent cause of shock, accounting for 62 % of cases, followed by cardiogenic shock (17 %) and hypovolemia (16 %) [8].”
BackgroundHotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J.-L. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.45 · Cited by 1,620
Self-citationPeerapornratana, S., Manrique-Caballero, C. L., Gómez, H., & Kellum, J. A. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.026 · Cited by 1,471
Vincent, J.-L., & De Backer, D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208943 · Cited by 1,425
Self-citationDrotrecogin Alfa (Activated) in Adults with Septic Shock
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202290 · Cited by 1,309
“We used an adaptive design(22) that allowed us to increase the sample size to maintain adequate statistical power, since some trials involving patients with severe sepsis showed lower-thanexpected mortality.(19,23,24) To reduce the risk of assignment bias, we concealed study-group assignments before and after randomiz…”
MethodHigh versus low blood-pressure target in patients with septic shock.
Asfar, P., Meziani, F., Hamel, J.-F., Grelon, F., Megarbane, B., Anguel, N., Mira, J.-P., Dequin, P.-F., Gergaud, S., Weiss, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312173 · Cited by 1,239
Mehta, R. L., Cerdá, J., Burdmann, E. A., Tonelli, M., García-García, G., Jha, V., Susantitaphong, P., Rocco, M., Vanholder, R., Sever, M. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60126-x · Cited by 1,154
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., & Zhou, R. (2015) · Cell · doi:10.1016/j.cell.2014.11.047 · Cited by 1,014
Konstam, M. A., Kiernan, M. S., Bernstein, D., Bozkurt, B., Jacob, M., Kapur, N. K., Kociol, R. D., Lewis, E. F., Mehra, M. R., Pagani, F. D., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000560 · Cited by 945
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury
Palevsky, P. M., Liu, K. D., Brophy, P. D., Chawla, L. S., Parikh, C. R., Thakar, C. V., Tolwani, A. J., Waikar, S. S., & Weisbord, S. D. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.349 · Cited by 935
“658 was associated with more adverse events in those with sepsis and with an increased risk of death in those with cardiogenic shock.(44) In a subsequent meta-analysis and systematic review of patients with septic shock, dopamine was associated with an increased risk of death and arrhythmias.”
BackgroundAngiotensin II for the Treatment of Vasodilatory Shock
Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Altaweel, L., Albertson, T. E., Mackey, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704154 · Cited by 916
Sepsis associated acute kidney injury
Poston, J. T., & Koyner, J. L. (2019) · BMJ · doi:10.1136/bmj.k4891 · Cited by 818
Clinical Picture and Risk Prediction of Short-Term Mortality in Cardiogenic Shock
Harjola, V.-P., Lassus, J., Sionis, A., Køber, L., Tarvasmäki, T., Spinar, J., Parissis, J., Banaszewski, M., Silva-Cardoso, J., Carubelli, V., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.260 · Cited by 790
Management of cardiogenic shock complicating myocardial infarction: an update 2019
Thiele, H., Ohman, E. M., de Waha-Thiele, S., Zeymer, U., & Desch, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz363 · Cited by 683
“The predefined CS subgroup—the percentage of CS due to AMI is not reported—had lower mortality with norepinephrine.(50) Comparing epinephrine and norepinephrine, two small randomized trials in CS showed similar effects of on cardiac index.”
ResultMetra, M., & Teerlink, J. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31071-1 · Cited by 673
Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000745 · Cited by 625
De Backer, D., Donadello, K., Sakr, Y., Ospina-Tascon, G., Salgado, D., Scolletta, S., & Vincent, J.-L. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182742e8b · Cited by 576
“As different vasopressor agents were used, we computed an aggregate vasopressor dose based on large randomized studies (25, 26): (0.”
MethodSelf-citationSepsis: The evolution in definition, pathophysiology, and management
Gyawali, B., Ramakrishna, K., & Dhamoon, A. S. (2019) · SAGE Open Medicine · doi:10.1177/2050312119835043 · Cited by 512
Chioncel, O., Parissis, J., Mebazaa, A., Thiele, H., Desch, S., Bauersachs, J., Harjola, V.-P., Antohi, E.-L., Arrigo, M., Ben Gal, T., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1922 · Cited by 493
Management of cardiogenic shock
Thiele, H., Ohman, E. M., Desch, S., Eitel, I., & de Waha, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv051 · Cited by 477
“The predefined CS subgroup—the percentage of CS due to AMI is not reported—had lower mortality with norepinephrine (Figure 1).(31) Therefore, when blood pressure is low, norepinephrine should be the first choice as vasopressor.”
BackgroundEpinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction
Levy, B., Clere-Jehl, R., Legras, A., Morichau-Beauchant, T., Leone, M., Frederique, G., Quenot, J.-P., Kimmoun, A., Cariou, A., Lassus, J., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.051 · Cited by 477
“In a randomized study comparing dopamine and norepinephrine (8), a subgroup analysis of 280 patients with CS found that dopamine was associated with increased 28-day mortality compared with norepinephrine, leading to a progressive decrease in dopamine use in this indication (9).”
Ibánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
“Dobutamine is the initial therapy for patients with predominant low cardiac output, whereas norepinephrine may be safer and more effective than dopamine in patients with cardiogenic shock and severe hypotension.(428) Levosimendan may be considered as an alternative, especially for patients on chronic beta-blocker ther…”
BackgroundMechanical circulatory support in cardiogenic shock
Werdan, K., Gielen, S., Ebelt, H., & Hochman, J. S. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht248 · Cited by 454
Atherton, J. J., Sindone, A., De Pasquale, C. G., Driscoll, A., MacDonald, P. S., Hopper, I., Kistler, P. M., Briffa, T., Wong, J., Abhayaratna, W., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1042 · Cited by 431
“Vasopressor inotropic agents such as noradrenaline (norepinephrine), high-dose dopamine or adrenaline (epinephrine) are indicated in patients with marked hypotension, to increase blood pressure and improve perfusion to vital organs when there is an inadequate response to inotropic therapy with or without intravenous f…”
BackgroundCardiogenic Shock After Acute Myocardial Infarction: A Review
Samsky, M. D., Morrow, D. A., Proudfoot, A. G., Hochman, J. S., Thiele, H., & Rao, S. V. (2021) · JAMA · doi:10.1001/jama.2021.18323 · Cited by 431
Harjola, V.-P., Mullens, W., Banaszewski, M., Bauersachs, J., Brunner-La Rocca, H.-P., Chioncel, O., Collins, S. P., Doehner, W., Filippatos, G. S., Flammer, A. J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.872 · Cited by 430
Sepsis and Septic Shock – Basics of diagnosis, pathophysiology and clinical decision making
Font, M. D., Thyagarajan, B., & Khanna, A. K. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.02.011 · Cited by 420
“However, randomized trials comparing the use of dopamine versus norepinephrine as an initial agent showed higher incidences of tachyarrhythmia and worsened mortality with dopamine compared with norepinephrine.(61) Hence, the recommendation from the Surviving Sepsis Campaign that norepinephrine be used as a first-line…”
ResultAndrews, B., Semler, M. W., Muchemwa, L., Kelly, P., Lakhi, S., Heimburger, D. C., Mabula, C., Bwalya, M., & Bernard, G. R. (2017) · JAMA · doi:10.1001/jama.2017.10913 · Cited by 418
“Time since HIV diagnosis, median (IQR), d 90 (30-1095) 75 (14-730)”
Background(2015) · doi:10.1002/ejhf.289 · Cited by 417
Lactic Acidosis in Sepsis: It’s Not All Anaerobic
Suetrong, B., & Walley, K. R. (2016) · Chest · doi:10.1378/chest.15-1703 · Cited by 401
2019 EACTS Expert Consensus on long-term mechanical circulatory support
Potapov, E. V., Antonides, C., Crespo-Leiro, M. G., Combes, A., Färber, G., Hannan, M. M., Kukucka, M., de Jonge, N., Loforte, A., Lund, L. H., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz098 · Cited by 399
Berg, M. D., Schexnayder, S. M., Chameides, L., Terry, M., Donoghue, A., Hickey, R. W., Berg, R. A., Sutton, R. M., & Hazinski, M. F. (2010) · Pediatrics · doi:10.1542/peds.2010-2972c · Cited by 398
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis*
De Backer, D., Aldecoa, C., Njimi, H., & Vincent, J.-L. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31823778ee · Cited by 389
“Two recent systematic reviews by Vasu et al (17) and by Havel et al (18) have evaluated the effects of dopamine and norepinephrine on the outcome of patients with shock, but these reviews also included data from patients with other types of shock than septic shock, which may have driven the results (15).”
BackgroundMethodResultInfluentialSelf-citationPrice, L. C., Wort, S. J., Finney, S. J., Marino, P. S., & Brett, S. J. (2010) · Critical Care · doi:10.1186/cc9264 · Cited by 389
Reappraisal of Ventilator-Free Days in Critical Care Research
Yehya, N., Harhay, M. O., Curley, M. A. Q., Schoenfeld, D. A., & Reeder, R. W. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-2050cp · Cited by 385
Organ Dysfunction in Sepsis: An Ominous Trajectory From Infection To Death.
Caraballo, C., & Jaimes, F. A. (2019) · PubMed Central · Cited by 371
Management of bacterial infections in cirrhosis
Fernández, J., & Gustot, T. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60002-6 · Cited by 368
Mareev, V. Y., Medical Scientific and Educational Centre of Moscow State University, Fomin, I. V., Federal State Budgetary Educational Institution of Higher Education, ". N. S. M. A. O. T. M. O. H. O. T. R. F., Ageev, F. T., Federal State Budgetary Institution, ". C. S. A. P. C. O. T. M. O. H. O. T. R. F., Begrambekova, Y. L., Federal State Budgetary Educational Institution of Higher Education, ". V. L. M. S. U., Vasyuk, Y. A., Federal State Budgetary Educational Institution of Higher Education, ". I. E. M. S. U. F. M. A. D. O. T. M. O. H. O. T. R. F., et al. (2018) · Kardiologiia · doi:10.18087/cardio.2475 · Cited by 361
Martin, L., Derwall, M., Al Zoubi, S., Zechendorf, E., Reuter, D. A., Thiemermann, C., & Schuerholz, T. (2019) · Chest · doi:10.1016/j.chest.2018.08.1037 · Cited by 360
“07).(72) Moreover, a meta-analysis (11 randomized trials with 1,710 patients) confirms that the use of norepinephrine results in lower mortality (risk reduction, 0.”
BackgroundJoannidis, M., Druml, W., Forni, L. G., Groeneveld, A. B. J., Honore, P. M., Hoste, E., Ostermann, M., Oudemans-van Straaten, H. M., & Schetz, M. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4832-y · Cited by 340
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock
Mathew, R., Di Santo, P., Jung, R. G., Marbach, J. A., Hutson, J., Simard, T., Ramirez, F. D., Harnett, D. T., Merdad, A., Almufleh, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026845 · Cited by 326
Balk, R. A. (2014) · Virulence · doi:10.4161/viru.27135 · Cited by 315
Morrow, D. A., Fang, J. C., Fintel, D. J., Granger, C. B., Katz, J. N., Kushner, F. G., Kuvin, J. T., Lopez-Sendon, J., McAreavey, D., Nallamothu, B., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31826890b0 · Cited by 310
Myocardial depression in sepsis: From pathogenesis to clinical manifestations and treatment
Antonucci, E., Fiaccadori, E., Donadello, K., Taccone, F. S., Franchi, F., & Scolletta, S. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.03.028 · Cited by 307
“Moreover, dopamine has several adverse effects, including being associatedwithmore tachycardia and arrhythmias and a higher mortality in septic/cardiogenic shock states [138–141].”
BackgroundLevy, B., Perez, P., Perny, J., Thivilier, C., & Gerard, A. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181ffe0eb · Cited by 299
“Dopamine, which was initially considered as the drug of choice, should be abandoned since it has recently been demonstrated to increase mortality in cardiogenic shock (4).”
BackgroundManagement of the critically ill patient with cirrhosis: A multidisciplinary perspective
Nadim, M. K., Durand, F., Kellum, J. A., Levitsky, J., O’Leary, J. G., Karvellas, C. J., Bajaj, J. S., Davenport, A., Jalan, R., Angeli, P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.019 · Cited by 297
“Norepinephrine is the first line agent as it is associated with fewer adverse events [85].”
Self-citationVasoactive-Inotropic Score: Evolution, Clinical Utility, and Pitfalls
Belletti, A., Lerose, C. C., Zangrillo, A., & Landoni, G. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.09.117 · Cited by 295
Vasopressors for the treatment of septic shock: Systematic review and meta-analysis.
Avni, T., Lador, A., Lev, S., Leibovici, L., Paul, M., & Grossman, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129305 · Cited by 293
“triple blinded [15], 8 trials were double blinded [13, 24, 26, 27, 30–32, 36], 2 were single blinded [20, 34] and the others were open-labeled or not stated.”
BackgroundResultInfluentialTumlin, J. A., Murugan, R., Deane, A. M., Ostermann, M., Busse, L. W., Ham, K. R., Kashani, K., Szerlip, H. M., Prowle, J. R., Bihorac, A., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003092 · Cited by 291
J. Romero-Bermejo, F., Ruiz-Bailen, M., Gil-Cebrian, J., & J. Huertos-Ranchal, M. (2011) · Current Cardiology Reviews · doi:10.2174/157340311798220494 · Cited by 287
Surviving sepsis campaign: research priorities for sepsis and septic shock
Coopersmith, C. M., De Backer, D., Deutschman, C. S., Ferrer, R., Lat, I., Machado, F. R., Martin, G. S., Martin-Loeches, I., Nunnally, M. E., Antonelli, M., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5175-z · Cited by 281
Patel, S. M., Lipinski, J., Al-Kindi, S. G., Patel, T. R., Saric, P., Li, J., Nadeem, F., Ladas, T. P., Alaiti, A., Phillips, A., et al. (2018) · ASAIO Journal · doi:10.1097/mat.0000000000000767 · Cited by 277
Henry, T. D., Tomey, M. I., Tamis-Holland, J. E., Thiele, H., Rao, S. V., Menon, V., Klein, D. G., Naka, Y., Piña, I. L., Kapur, N. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000959 · Cited by 276
Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock
Leligdowicz, A., Dodek, P. M., Norena, M., Wong, H., Kumar, A., & Kumar, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1875oc · Cited by 274
The Physiologically Difficult Airway
Mosier, J., Joshi, R., Hypes, C., Pacheco, G., Valenzuela, T., & Sakles, J. (2015) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2015.8.27467 · Cited by 265
Fever Control Using External Cooling in Septic Shock: A Randomized Controlled Trial
Schortgen, F., Clabault, K., Katsahian, S., Devaquet, J., Mercat, A., Deye, N., Dellamonica, J., Bouadma, L., Cook, F., Beji, O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1820oc · Cited by 259
“All vasopressors can have unwanted effects on regional blood flow, heart rhythm, cardiac output, and acid–base balance (6, 7, 45).”
BackgroundTemporary circulatory support for cardiogenic shock
Combes, A., Price, S., Slutsky, A. S., & Brodie, D. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31047-3 · Cited by 257
McGill, F., Heyderman, R. S., Michael, B. D., Defres, S., Beeching, N. J., Borrow, R., Glennie, L., Gaillemin, O., Wyncoll, D., Kaczmarski, E., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.01.007 · Cited by 254
“Norepinephrine is the vasopressor of choice given that it has equivalent efficacy to dopamine but less adverse events.(198) Vasoactive agents such as norepinephrine should be initiated early in persistent shock, via a central vein.”
BackgroundIntensive Care Unit–acquired Weakness: Clinical Phenotypes and Molecular Mechanisms
Batt, J., dos Santos, C. C., Cameron, J. I., & Herridge, M. S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201205-0954so · Cited by 254
Perioperative acute kidney injury
Goren, O., & Matot, I. (2015) · British Journal of Anaesthesia · doi:10.1093/bja/aev380 · Cited by 251
“98 148 Compared with norepinephrine, dopamine is associated with more adverse events.(149) Phenylephrine is a potent vasoconstrictor, but with a profound α-adrenergic activity that causes vasoconstriction.”
BackgroundCreager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001415 · Cited by 250
Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study
Schmittinger, C. A., Torgersen, C., Luckner, G., Schröder, D. C. H., Lorenz, I., & Dünser, M. W. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2531-2 · Cited by 246
2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology, (. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4103 · Cited by 244
Vasoplegia treatments: the past, the present, and the future
Levy, B., Fritz, C., Tahon, E., Jacquot, A., Auchet, T., & Kimmoun, A. (2018) · Critical Care · doi:10.1186/s13054-018-1967-3 · Cited by 241
“Norepinephrine has numerous advantages when compared to other vasopressors, including: a) a very potent vasopressor effect equivalent to epinephrine and phenylephrine and higher than dopamine [25]; b) contrary to epinephrine, norepinephrine does not act on β2 adrenergic receptors—hence, lactate levels do not increase…”
BackgroundKleinman, M. E., de Caen, A. R., Chameides, L., Atkins, D. L., Berg, R. A., Berg, M. D., Bhanji, F., Biarent, D., Bingham, R., Coovadia, A. H., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.971093 · Cited by 240
Vasopressors for hypotensive shock
Gamper, G., Havel, C., Arrich, J., Losert, H., Pace, N. L., Müllner, M., & Herkner, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003709.pub4 · Cited by 239
Acute-on-Chronic Liver Failure Clinical Guidelines
Bajaj, J. S., O'Leary, J. G., Lai, J. C., Wong, F., Long, M. D., Wong, R. J., & Kamath, P. S. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001595 · Cited by 237
“When patients with ACLF develop circulatory failure and require pressor support, norepinephrine should be given because of efficacy and favorable safety profile (31,65).”
BackgroundManagement of Refractory Vasodilatory Shock
Jentzer, J. C., Vallabhajosyula, S., Khanna, A. K., Chawla, L. S., Busse, L. W., & Kashani, K. B. (2018) · Chest · doi:10.1016/j.chest.2017.12.021 · Cited by 236
“org benefit.(4,10,46,47) The consensus view is that norepinephrine should be the recommended first-line vasopressor for most critically ill patients in whom vascular tone needs to be increased.”
BackgroundMethodResultThe Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update?
Moreno, R., Rhodes, A., Piquilloud, L., Hernandez, G., Takala, J., Gershengorn, H. B., Tavares, M., Coopersmith, C. M., Myatra, S. N., Singer, M., et al. (2023) · Critical Care · doi:10.1186/s13054-022-04290-9 · Cited by 232
“While use of dopamine has declined considerably worldwide, it may still be used sufficiently to warrant retention [10, 11].”
BackgroundSelf-citationLandoni, G., Biondi-Zoccai, G., Greco, M., Greco, T., Bignami, E., Morelli, A., Guarracino, F., & Zangrillo, A. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318232962a · Cited by 232
“Annane et al (112) suggested that there is no evidence for a difference in efficacy and safety between epinephrine alone and norepinephrine plus dobutamine for the management of septic shock, while De Backer et al (113) found that there was no significant difference in the rate of death between patients with shock who…”
Backgroundfor the Canadian Critical Care Trials Group., Lamontagne, F., Meade, M. O., Hébert, P. C., Asfar, P., Lauzier, F., Seely, A. J. E., Day, A. G., Mehta, S., Muscedere, J., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4237-3 · Cited by 230
Sepsis and septic shock: Guideline-based management
Dugar, S., Choudhary, C., & Duggal, A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.18143 · Cited by 229
Mebazaa, A., Parissis, J., Porcher, R., Gayat, E., Nikolaou, M., Boas, F. V., Delgado, J. F., & Follath, F. (2011) · Intensive Care Medicine · doi:10.1007/s00134-010-2073-4 · Cited by 229
Burzotta, F., Trani, C., Doshi, S. N., Townend, J., van Geuns, R., Hunziker, P., Schieffer, B., Karatolios, K., Møller, J. E., Ribichini, F. L., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.065 · Cited by 229
Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01708-10 · Cited by 226
“The morbidity and mortality rates for sepsis and septic shock remain unacceptably high, with septic shock still associated with a 35 to 65% in-hospital mortality rate (5, 9).”
BackgroundSelf-citationVasopressor therapy in critically ill patients with shock
Russell, J. A. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05801-z · Cited by 226
Metadata
- Authors
- De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L.
- Affiliations
- Université Libre de Bruxelles (BE)
- Medical University of Vienna (AT)
- Centre hospitalier Etterbeek-Ixelles (BE)
- Erasmus Hospital (BE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 779-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095944485
- Cited by
- 1,940
- References
- 31
- Citations by year
- 2026: 98 · 2025: 107 · 2024: 140 · 2023: 115 · 2022: 125 · 2021: 132 · 2020: 135 · 2019: 138 · 2018: 106 · 2017: 139 · 2016: 99 · 2015: 122 · 2014: 120 · 2013: 96 · 2012: 110
- FWCI
- 83.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
- Keywords
- dopamine, norepinephrine, vasopressors, shock, cardiogenic shock, septic shock, hypovolemic shock, 28-day mortality, cardiac arrhythmias, epinephrine, vasopressin, organ support, adverse events, subgroup analysis, vasopressor weaning
- MeSH terms
- Aged, Arrhythmias, Cardiac, Combined Modality Therapy, Dopamine, Female, Fluid Therapy, Humans, Male, Middle Aged, Norepinephrine, Shock, Vasoconstrictor Agents, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.